Observation of changes in ocular findings before and after the use of the IL-4 and 13 antibody preparation dupilumab

Observation of changes in ocular findings before and after the use of the IL-4 and 13 antibody preparation dupilumab - dupilumab

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038675

Enrollment

150

Registered

2019-11-26

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis, bronchial asthma, sinusitis, and ocular disorders

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients using dupilumab who have accepted ophthalmologic examinations and this study

Exclusion criteria

Exclusion criteria: Patients who have refused to provide clinical information to this study

Design outcomes

Primary

Measure	Time frame
Visual acuity, intraocular pressure, refractive value, corneal curvature radius, axial length, Schirmer test, fluorescein score, Rose Bengal or Lissaing Lean score, tear film breakup time, subjective symptom OSDI, optic nerve flicker, imaging findings, blood sampling test, tear fluid, cytology, etc.	—

Countries

Japan

Contacts

Public ContactEisuke Shimizu

Department of Ophthalmology, Keio University School of Medicine Ophthalmology

ophthalmolog1st.acek39@gmail.com03-5363-3821

Outcome results